HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NanoBio Nasal Antiseptic, Burst Oral-Care Probiotics And More: Personal Care Launch News

Executive Summary

Recent personal-care product launches show companies innovating in emerging frontiers and hazily regulated territory with probiotic oral care, over-the-counter fungal nail care and nasal antiseptic care. Elsewhere, sensitive skin specialist Cetaphil introduces ultra-moisturizing products, and Nestle Health Sciences’ Atrium Innovations launches a line of nutritional supplements for skin, hair and nail health.

You may also be interested in...



UK Researchers Seek Commercial Partner For Nasal Spray Shown To ‘Prevent’ COVID-19

A nasal spray formulated using compounds already approved by regulatory bodies in Europe and the US can “prevent and slow” transmission of COVID-19, according to UK researchers who are now seeking a partner to commercialize the product.

Bausch Considers Proposal For COVID-19 Drug: Lumify Eye Drops Inactivate Virus In Lab Tests

Bausch Health says its Lumify OTC redness reliever drops showed "complete inactivation" of COVID-19 in time-kill tests, with preservative compound benzalkonium chloride apparently the key reason. The in vitro findings prompted it to consider discussions with regulatory agencies on proposing a remedy for the virus.

NAD Case Reopened, But Fungi-Nail Marketer Fails Again With ‘#1 Pharmacist Recommended’ Claim

New Jersey-based Arcadia Consumer Healthcare, Inc., succeeded in reopening a 2018 National Advertising Division case involving its ‘#1 Pharmacist Recommended’ claim for the Fungi-Nail line, but failed again to convince the NAD that survey findings justify the claim.

Related Content

Topics

UsernamePublicRestriction

Register

RS150550

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel